MEDICURE INC

MEDICURE INC

Medicure was founded in 1997 by Albert D. Friesen, a biochemist who previously founded the Canadian blood-products business that became Cangene. The company went public on the TSX Venture Exchange (later the TSX) and built its commercial position around two FDA-approved cardiovascular drugs — Aggrastat (tirofiban) and Zypitamag (pitavastatin) — that anchor its revenue base. The firm operates as a drug commercialization platform rather than a diversified allocator. Its primary asset is Aggrastat, an antiplatelet agent used in acute coronary syndrome, acquired from Merck in 2006 after the latter discontinued US marketing. The second pillar is Zypitamag, a branded generic statin positioned as an alternative to the more widely prescribed Lipitor. The model is concentrated and product-specific — Medicure takes established or under-marketed hospital/cardiology drugs and runs targeted physician-sales campaigns, primarily in the United States, through its subsidiary Medicure International Inc. Medicure scaled its revenue from a single-digit million base to over $20 million annually by the mid-2010s, driven by Aggrastat's hospital formulary placement. The company maintains a lean corporate footprint with its head office in Winnipeg, Manitoba, and a US commercial operation in Plymouth, Minnesota. It has periodically explored acquiring additional mature cardiovascular or metabolic assets that fit its call-point model, though no major deal has closed since the launch of Zypitamag. In October 2015, the company announced a normal course issuer bid to repurchase up to 5% of its outstanding common shares (per the firm, October 2015). Medicure's structural differentiator is that it is not an investment entity but an operating pharmaceutical company that maintains a micro-cap public listing — making it a rare publicly accessible vehicle for a concentrated bet on legacy acute-care drug cash flows. The governance sits with a board Friesen chairs, and the economic model generates operating earnings rather than management fees. This means allocators evaluating it must treat it as an equity security subject to drug-patent cliffs and FDA regulatory cycles, not a fund.